How nerve cells affect pancreatic cancer growth
Peripheral Nerve Regulation of Pancreas Cancer Progression
This work looks at how sensory and sympathetic nerve cells change immune responses and help pancreatic cancer progress.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11127669 on NIH RePORTER |
What this research studies
Researchers will use mouse models that develop pancreatic ductal adenocarcinoma and laboratory assays to observe how sensory and sympathetic nerves interact with immune cells in early tumors. They will examine proteins on nerve cells that resemble immune checkpoint molecules and test whether those nerve signals change immune activity around tumors. The team will also study how innervation of nearby lymph nodes changes and whether those nerve changes help tumors grow. Overall, the project combines imaging, molecular assays, and tissue analysis to identify nerve-related targets that could be relevant to patients.
Who could benefit from this research
Good fit: People with pancreatic ductal adenocarcinoma or those at high risk for pancreatic cancer would be the most relevant candidates for related future trials or sample collection.
Not a fit: Individuals without pancreatic disease or with non-ductal pancreatic tumors are unlikely to receive direct benefit from this specific line of work in the near term.
Why it matters
Potential benefit: If successful, this work could point to new ways to slow pancreatic cancer by targeting nerve-related signals or using nerve-based biomarkers to guide treatment.
How similar studies have performed: Previous animal studies showed that removing or blocking sensory nerves can slow pancreatic cancer progression in mice, but translating this finding to human therapies and targeting neuronal checkpoint proteins remains novel.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Saloman, Jami Lynn — University of Pittsburgh at Pittsburgh
- Study coordinator: Saloman, Jami Lynn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.